Pages that link to "Q46496013"

The following pages link to Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone (Q46496013):

Displaying 42 items.

• Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation (Q31118020) (← links)
• Validation of an LC/MS method for the determination of gemfibrozil in human plasma and its application to a pharmacokinetic study (Q33746585) (← links)
• Pharmacokinetic interactions with thiazolidinediones (Q34573733) (← links)
• CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast (Q35718619) (← links)
• Effect of rifampicin on the pharmacokinetics of pioglitazone (Q35827325) (← links)
• Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions (Q36349758) (← links)
• No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone (Q36536042) (← links)
• Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone (Q36562502) (← links)
• Fibrates: what have we learned in the past 40 years? (Q36742410) (← links)
• Drug-drug interaction between voriconazole and oral hypoglycemic agents in diabetic rats. (Q36865457) (← links)
• Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers (Q37141923) (← links)
• Drug-induced hypoglycaemia: an update (Q37799813) (← links)
• Towards safer and more predictable drug treatment--reflections from studies of the First BCPT Prize awardee (Q37986145) (← links)
• Thiazolidinedione safety (Q38012205) (← links)
• PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. (Q38130410) (← links)
• Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactions (Q38253580) (← links)
• Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes (Q38455771) (← links)
• Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions (Q38684505) (← links)
• Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters (Q38811728) (← links)
• Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. (Q38933872) (← links)
• Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies. (Q39779416) (← links)
• Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863. (Q39810440) (← links)
• Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. (Q40074903) (← links)
• Evaluation of CYP2C8 Inhibition In Vitro: Utility of Montelukast as a Selective CYP2C8 Probe Substrate (Q43503022) (← links)
• Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. (Q45923722) (← links)
• Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite. (Q46431899) (← links)
• The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo (Q46664324) (← links)
• Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide (Q46919666) (← links)
• Pioglitazone. Review of its metabolic and systemic effects (Q46982956) (← links)
• Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans. (Q49685370) (← links)
• Physiologically based pharmacokinetics model predicts the lack of inhibition by repaglinide on the metabolism of pioglitazone (Q50864429) (← links)
• Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases (Q51636744) (← links)
• Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone. (Q53086784) (← links)
• Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel (Q57825080) (← links)
• Gemfibrozil Is a Strong Inactivator of CYP2C8 in Very Small Multiple Doses (Q57825117) (← links)
• Itraconazole, a P-Glycoprotein and CYP3A4 Inhibitor, Markedly Raises the Plasma Concentrations and Enhances the Renin-Inhibiting Effect of Aliskiren (Q57825127) (← links)
• Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen (Q57825141) (← links)
• Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone (Q57825155) (← links)
• Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide (Q57825160) (← links)
• The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast (Q60449842) (← links)
• The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone (Q60449866) (← links)
• Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole (Q92299350) (← links)